Skip to content
Cadralazine
Cadralazine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Requested
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02D: Arteriolar smooth muscle, agents acting on
— C02DB: Hydrazinophthalazine derivatives acting on arteriolar smooth muscle
— C02DB04: Cadralazine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCADRALAZINE
INNcadralazine
Description
Cadralazine is an organic molecular entity.
Classification
Small molecule
Drug classantihypertensives (hydrazine-phthalazines); antiarrhythmic/antianginal/antihypertensive agents, phthalazine like structure
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOC(=O)NNc1ccc(N(CC)CC(C)O)nn1
Identifiers
PDB—
CAS-ID64241-34-5
RxCUI—
ChEMBL IDCHEMBL2106561
ChEBI ID—
PubChem CID2515
DrugBankDB13452
UNII ID8T96I3U713 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 21 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
218 adverse events reported
View more details